Miles Hartman
Psychiatric/Mental Health · Creve Coeur, MONPI 1760948574
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 345 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,590 and has fallen 77.1% since, to $594 in 2025. Among psychiatric/mental health clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 345 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$884
- Teva Pharmaceuticals USA, Inc.$800
- Acadia Pharmaceuticals Inc$447
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$441
- Neurocrine Biosciences, Inc.$410
- Jazz Pharmaceuticals Inc.$309
- plus $2K from 14 others
What the payments were for
- Food & beverage$5,43497%
- Education$1703%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 67 | $884 |
| Teva Pharmaceuticals USA, Inc. | 45 | $800 |
| Acadia Pharmaceuticals Inc | 11 | $447 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 39 | $441 |
| Neurocrine Biosciences, Inc. | 21 | $410 |
| Jazz Pharmaceuticals Inc. | 23 | $309 |
| Avanir Pharmaceuticals, Inc. | 16 | $298 |
| Johnson & Johnson | 14 | $290 |
| Sun Pharmaceutical Industries Inc. | 24 | $281 |
| AbbVie | 16 | $268 |
| Sunovion Pharmaceuticals Inc. | 17 | $268 |
| Otsuka America Pharmaceutical, Inc. | 5 | $206 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $147 |
| Bausch Health US, LLC | 19 | $134 |
| Janssen Scientific Affairs, LLC | 1 | $130 |
| Vanda Pharmaceuticals Inc. | 7 | $129 |
| Indivior Inc. | 4 | $69 |
| Noven Therapeutics, LLC | 3 | $50 |
| Neos Therapeutics, LP | 1 | $22 |
| Merck | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$480
- LYBALVI$460
- NUPLAZID$246
- INGREZZA$140
- INVEGA SUSTENNA$130
- AUSTEDO$123
- ARISTADA INITIO$120
- REXULTI$110
How this compares
$5,604 in reported general payments places this provider in the 90th percentile of 565 psychiatric/mental health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 97 | $335,531 |
| AristadaAripiprazole Lauroxil | 25 | $67,054 |
| Aripiprazole | 463 | $26,512 |
| RexultiBrexpiprazole | 16 | $20,621 |
| Clozapine | 217 | $19,097 |
| Haloperidol | 571 | $18,775 |
| Paliperidone ErPaliperidone | 53 | $17,992 |
| Olanzapine | 495 | $10,678 |
| TrintellixVortioxetine Hydrobromide | 28 | $9,863 |
| Divalproex Sodium | 301 | $9,758 |
| Chlorpromazine Hcl | 59 | $8,648 |
| VraylarCariprazine Hcl | 11 | $8,157 |
| Mirtazapine | 333 | $7,678 |
| Memantine Hcl ErMemantine Hcl | 77 | $7,517 |
| Lurasidone Hcl | 36 | $7,028 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $290 | $335,53197 claims |
| Alkermes, Inc.Aristada | $884 | $67,05425 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $206 | $20,62116 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $147 | $9,86328 claims |
| AbbVieVraylar | $268 | $8,15711 claims |
| MerckBelsomra | $20 | $4,47828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Creve Coeur
- Jeffery DavisCreve Coeur$24K
- Elizabeth BerryCreve Coeur$9K
- Michelle GarrettCreve Coeur$6K
- Aldijana SacicSaint Louis$510K
- Erin DuvallSpringfield$275K
- Laurel OwensLees Summit$246K
- Julie WaterburySaint Louis$135K
- Emily WoukSpringfield$90K
- Kristerpher BrimberryPoplar Bluff$74K
- Matthew LindquistSt Louis$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.